Effects of case management and new drugs on Medicaid AIDS spending.
This study evaluates the effects of Florida's participation in the Medicaid acquired immunodeficiency syndrome (AIDS) home and community-based waiver and the use of recently developed AIDS drugs on spending per Medicaid beneficiary. We find that monthly Medicaid spending for waiver non-participants was significantly higher than was spending for waiver nonparticipants. The major reason for the cost difference is that nonwaiver enrollees incurred significantly higher inpatient costs than did those enrolled in the waiver. Although waiver enrollees had higher drug spending, these represent only a fraction of the higher inpatient costs incurred by nonwaiver enrollees. Thus, it appears that adherence to appropriate medications reduces the need for inpatient care. The case management approach of the AIDS waiver may have similar effects for persons with other chronic diseases.
Georgetown University Public Policy Institute in Washington, D.C., USA.
J M
JM
Mitchell
K H
KH
Anderson
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000191:economics*; D000328:Adult; D019380:Anti-HIV Agents / Q000191:economics*; D019090:Case Management / Q000191:economics*; D003363:Cost Control; D016527:Drug Costs / Q000706:statistics & numerical data; D005431:Florida; D005102:Health Expenditures / Q000706:statistics & numerical data / Q000639:trends*; D006801:Humans; D008484:Medicaid / Q000706:statistics & numerical data*; D010343:Patient Admission / Q000191:economics; D013221:State Health Plans / Q000191:economics / Q000458:organization & administration; D014481:United States
D019380:Anti-HIV Agents